Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:11:58.377Z.
Calculation as of: 2026-10-06T15:11:58.377Z.
Quote observation: 2026-10-06T15:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.95B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.95B
EV/FCF Ratio
742.38x
TTM Avg
495.80x
3Y Avg
11749.41x
5Y Avg
11749.41x
Market Cap
$1.99B
EV/FCF Ratio
16.14x
TTM Avg
20.29x
3Y Avg
742.45x
5Y Avg
860.87x
Market Cap
$1.89B
EV/FCF Ratio
N/A
TTM Avg
539.27x
3Y Avg
437.29x
5Y Avg
621.70x
Market Cap
$1.88B
EV/FCF Ratio
N/A
TTM Avg
34.54x
3Y Avg
34.54x
5Y Avg
34.54x
Market Cap
$2.02B
EV/FCF Ratio
10.96x
TTM Avg
15.23x
3Y Avg
21.85x
5Y Avg
21.85x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.95B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 742.38x | 495.80x | 11749.41x | 11749.41x |
| Immunome, Inc. (IMNM)vs › | $1.96B | N/A | 28.11x | 28.11x | 28.11x |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.99B | 16.14x | 20.29x | 742.45x | 860.87x |
| Azenta, Inc. (AZTA)vs › | $1.91B | 179.33x | 49.00x | 83.04x | 82.00x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | N/A | 539.27x | 437.29x | 621.70x |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.88B | N/A | 34.54x | 34.54x | 34.54x |
| Novavax, Inc. (NVAX)vs › | $1.88B | N/A | 19.57x | 82.87x | 82.87x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 10.96x | 15.23x | 21.85x | 21.85x |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.03B | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
